Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.

Participants needed: 786
Trial details
Phase: Phase 3Age: 12-80Biological sex: AllType: InterventionalSponsor: Generate BiomedicinesUpdated: Oct 7, 2026Locations: 132
Eligibility criteria

Adults and adolescents ≥ 12 and ≤ 80 years of age. [+8]

Subjects who experience a clinically significant asthma exacerbation within 12 w... [+28]

Read more
Status: Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

The objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.

Participants needed: 786
Trial details
Phase: Phase 3Age: 12-80Biological sex: AllType: InterventionalSponsor: Generate BiomedicinesUpdated: Oct 7, 2026Locations: 123
Eligibility criteria

Adults and adolescents ≥ 12 and ≤ 80 years of age. [+8]

Subjects who experience a clinically significant asthma exacerbation within 12 w... [+28]

Read more
Status: Recruiting

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.

Participants needed: 37
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Generate BiomedicinesUpdated: Jun 18, 2026Locations: 10
Eligibility criteria

Planned to receive standard-of-care treatment with enfortumab vedotin (EV) (star... [+6]

Previously received enfortumab vedotin (EV) or other MMAE-based antibody-drug co... [+9]

Read more